Quarterly report [Sections 13 or 15(d)]

STOCKHOLDERS' EQUITY (Details)

v3.25.1
STOCKHOLDERS' EQUITY (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 21, 2024
USD ($)
D
$ / shares
shares
Sep. 08, 2023
USD ($)
D
$ / shares
shares
Oct. 25, 2022
USD ($)
$ / shares
shares
Jan. 31, 2024
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
shares
Oct. 31, 2022
shares
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         24,582,748        
Common stock par value | $ / shares         $ 0.00001   $ 0.00001    
Net proceeds from warrant exercises | $           $ 43,849,467      
Warrant liability | $         $ 2,058,000   $ 1,718,000    
Exercise of warrants into common shares | $           $ 2,298,143      
Number of warrants exercised             547,177    
September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Gross proceeds | $   $ 24,500,000              
Net proceeds | $   $ 22,200,000              
October 2022 Public Offering and Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares     3,275,153            
Proceeds from exercise of warrants | $             $ 1,100,000    
Exercise price of warrants (in dollars per share) | $ / shares     $ 2.085            
Gross proceeds | $     $ 10,700,000            
Estimated offering expenses | $     $ 9,600,000            
Common Stock                  
STOCKHOLDERS' EQUITY                  
Exercise of warrants into common shares (in shares)           547,177      
Exercise of warrants into common shares | $           $ 5      
Common Stock | October 2022 Public Offering and Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares     1,875,945            
Exercise price of warrants (in dollars per share) | $ / shares     $ 1.96            
Common Stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Common stock par value | $ / shares   $ 1.82              
Convertible preferred shares issued   9,947,684              
Series E Warrants | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Share price | $ / shares   $ 20,000              
Series E-1 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Convertible preferred shares issued   13,461,538              
Conversion price per share | $ / shares   $ 1.82              
Shares issued   1,225              
Gross proceeds from stockholders' equity | $   $ 17,820,000              
Series E-2 Preferred Stock                  
STOCKHOLDERS' EQUITY                  
Preferred stock, share outstanding         35.6   35.60    
Series E-2 Preferred Stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Convertible preferred shares issued   13,461,538              
Conversion price per share | $ / shares   $ 1.82              
Conversion of preferred shares into common shares (in shares)             284.16    
Number of shares converted   905.24              
Preferred stock, share outstanding         35.6     319.76  
Series E-2 Preferred Stock | Common Stock                  
STOCKHOLDERS' EQUITY                  
Conversion of preferred shares into common shares (in shares)           903,956      
Series E-2 Preferred Stock | Common Stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Conversion of preferred shares into common shares (in shares)             3,122,637    
Series E-3 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Convertible preferred shares issued   13,846,154              
Conversion price per share | $ / shares   $ 3.185   $ 3.185          
Series E-3 preferred stock | Common Stock                  
STOCKHOLDERS' EQUITY                  
Conversion of preferred shares into common shares (in shares)         13,846,141 9,890,099      
Series E-4 preferred stock                  
STOCKHOLDERS' EQUITY                  
Fair value of the warrants allocated to preferred stock | $ $ 15,900,000                
Series E-4 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Convertible preferred shares issued   7,179,487              
Conversion price per share | $ / shares   $ 4.7775              
Series E-4 preferred stock | Common Stock                  
STOCKHOLDERS' EQUITY                  
Conversion of preferred shares into common shares (in shares)             6,739,919    
Tranche A and B Warrants | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Gross proceeds from stockholders' equity | $   $ 4,800,000              
Common Stock | October 2022 Public Offering and Private Placement                  
STOCKHOLDERS' EQUITY                  
Conversion of preferred shares into common shares (in shares)         0   1,079,132    
July 2024 Warrants                  
STOCKHOLDERS' EQUITY                  
Warrant liability | $ 12,000,000       $ 1,570,000   $ 1,200,000    
Fair value of warrants | $ 17,000,000                
Prefunded Warrant | October 2022 Public Offering and Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares     1,875,945            
pre-funded warrants             1,079,132    
Tranche A Warrants | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants term       10 days          
Tranche A Warrants | Series E-3 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Proceeds from exercise of warrants | $       $ 44,100,000          
Exercise of warrants into common shares (in shares)       2,205          
Exercise of warrants into common shares | $       $ 42,800,000          
2023 Tranche A Preferred Warrants | Series E-3 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares   2,205              
Proceeds from exercise of warrants | $   $ 44,100,000              
Number of days | D   10              
2023 Tranche B Preferred Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         439,560        
Exercise price of warrants (in dollars per share) | $ / shares         $ 4.7775        
Exercise or Settlement of warrants | $ $ 2,600,000                
2023 Tranche B Preferred Warrants | Series E-4 preferred stock                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares 1,610                
Number of shares issuable upon conversion of preferred stock 6,739,919                
Conversion price per share | $ / shares $ 2.52                
Proceeds from exercise of warrants | $ $ 19,400,000                
Net proceeds from warrant exercises | $ $ 17,500,000                
Preferred stock, par value (in dollars per share) | $ / shares $ 0.00001                
2023 Tranche B Preferred Warrants | Series E-4 preferred stock | September 2023 Private Placement                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares   1,715              
Proceeds from exercise of warrants | $   $ 34,300,000              
Number of days | D   10              
2022 Pre-Funded Common Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares                 1,875,941
2022 Pre-Funded Common Warrants | October 2022 Public Offering and Private Placement                  
STOCKHOLDERS' EQUITY                  
Exercise price of warrants (in dollars per share) | $ / shares     $ 0.00001            
Purchase price | $ / shares     $ 2.08499            
2022 Common Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         4,201,044        
Exercise price of warrants (in dollars per share) | $ / shares         $ 1.96        
2024 Tranche A Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         6,739,918        
Exercise price of warrants (in dollars per share) | $ / shares $ 2.52       $ 2.52        
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA | D 10                
2024 Tranche B Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         8,214,278        
Exercise price of warrants (in dollars per share) | $ / shares $ 4       $ 4        
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA | D 10                
2024 Tranche C Warrants                  
STOCKHOLDERS' EQUITY                  
Warrants issued to purchase shares         4,267,152        
Exercise price of warrants (in dollars per share) | $ / shares $ 5.5       $ 5.5        
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. | D 10                
Threshold amount of quarterly gross revenues trigger for expiry of warrants | $ $ 10,000,000